MedTrace Logo

Dose-Range Finding Study for MK0893 (0893-008)

NCT00479466 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 342

Last updated 2015-09-09

Study results available
· View outcomes & findings →

Summary

A study to compare MK0893 to metformin or placebo for patients with Type 2 diabetes (Diabetes Mellitus).

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

MK0893

MK0893 taken orally once daily; 20 mg and 40 mg tablets used in combination according to dose.

DRUG

Metformin

Metformin HCL 500 mg tablet twice daily titrating up to 1000 mg twice daily over 3 weeks.

DRUG

Placebo to MK0893

Dose-matched placebo tablets to MK0893; taken orally once daily.

DRUG

Placebo to Metformin

Dose-matched placebo tablets to metformin (500 mg); taken orally twice daily.

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2008-05-31
Completion
2008-05-31

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00479466 on ClinicalTrials.gov